|
1
|
Ferlay J, Soerjomataram I, Ervik M, Forman
D, Bray F, Dikshit R, Elser S, Mathers C, Rebelo M and Parkin DM:
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11. International Agency for Research on Cancer;
Lyon, France: 2013, Available from: http://globocan.iarc.fr,
accessed on day/month/year.
|
|
2
|
Howlader N, Noone A, Krapcho M, Miller D,
Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et
al: SEER Cancer Statistics Review, 1975–2013. National Cancer
Institute; Bethesda, MD: 2017
|
|
3
|
Ginsberg RJRL and Rubinstein LV; Lung
Cancer Study Group. Randomized trial of lobectomy versus limited
resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg.
60:615–622; discussion 622–623. 1995. View Article : Google Scholar
|
|
4
|
Timmerman R, Paulus R, Galvin J, Michalski
J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone
D, et al: Stereotactic body radiation therapy for inoperable early
stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deng B, Wang B, Fang J, Zhu X, Cao Z, Lin
Q, Zhou L and Sun X: MiRNA-203 suppresses cell proliferation,
migration and invasion in colorectal cancer via targeting of
EIF5A2. Sci Rep. 6:283012016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Z, Ma B, Ji X, Deng Y, Zhang T, Zhang
X, Gao H, Sun H, Wu H, Chen X, et al: MicroRNA-378-5p suppresses
cell proliferation and induces apoptosis in colorectal cancer cells
by targeting BRAF. Cancer Cell Int. 15:402016. View Article : Google Scholar
|
|
8
|
Shivdasani RA: MicroRNAs: Regulators of
gene expression and cell differentiation. Blood. 108:3646–3653.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Phuah NH, In LLA, Azmi MN, Ibrahim H,
Awang K and Nagoor NH: Alterations of MicroRNA expression patterns
in human cervical carcinoma cells (Ca Ski) toward
10S-10-acetoxychavicol acetate and cisplatin. Reprod Sci.
20:567–578. 2012. View Article : Google Scholar
|
|
10
|
Lin L, Tu HB, Wu L, Liu M and Jiang GN:
MicroRNA-21 regulates non-small cell lung cancer cell invasion and
chemosensitivity through SMAD7. Cell Physiol Biochem. 38:2152–2162.
2016. View Article : Google Scholar
|
|
11
|
Xiong S, Zheng Y, Jiang P, Liu R, Liu X
and Chu Y: MicroRNA-7 inhibits the growth of human non-small cell
lung cancer A549 cells through targeting BCL-2. Int J Biol Sci.
7:805–814. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tagscherer KE, Fassl A, Sinkovic T,
Richter J, Schecher S, Macher-Goeppinger S and Roth W: MicroRNA-210
induces apoptosis in colorectal cancer via induction of reactive
oxygen. Cancer Cell Int. 16:422016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu C, Zhang L, Li H, Liu Z, Duan L and Lu
C: MiRNA-1469 promotes lung cancer cells apoptosis through
targeting STAT5a. Am J Cancer Res. 5:1180–1189. 2015.PubMed/NCBI
|
|
15
|
Wu T, Chen W, Kong D, Li X, Lu H, Liu S,
Wang J, Du L, Kong Q, Huang X, et al: miR-25 targets the modulator
of apoptosis 1 gene in lung cancer. Carcinogenesis. 36:925–935.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu C, Li H, Zhang L, Jia T, Duan L and Lu
C: MicroRNA-1915-3p prevents the apoptosis of lung cancer cells by
downregulating DRG2 and PBX2. Mol Med Rep. 13:505–512. 2016.
View Article : Google Scholar
|
|
17
|
Jiang J, Huang J, Wang XR and Quan YH:
MicroRNA-202 induces cell cycle arrest and apoptosis in lung cancer
cells through targeting cyclin D1. Eur Rev Med Pharmacol Sci.
20:2278–2284. 2016.PubMed/NCBI
|
|
18
|
Zhang Y, Schiff D, Park D and Abounader R:
MicroRNA-608 and microRNA-34a regulate chordoma malignancy by
targeting EGFR, Bcl-xL and MET. PLoS One. 9:e915462014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang H, Li Q, Niu J, Li B, Jiang D, Wan Z,
Yang Q, Jiang F, Wei P and Bai S: microRNA-342-5p and miR-608
inhibit colon cancer tumorigenesis by targeting NAA10. Oncotarget.
7:2709–2720. 2016. View Article : Google Scholar :
|
|
20
|
Wang Z, Xue Y, Wang P, Zhu J and Ma J:
MiR-608 inhibits the migration and invasion of glioma stem cells by
targeting macrophage migration inhibitory factor. Oncol Rep.
35:2733–2742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu J, Sun J, Gu J, Liu G and Huizhu S:
MicroRNA-608 inhibits the cell proliferation in osteosarcoma by
macrophage migration inhibitory factor. Int J Clin Exp Pathol.
9:9166–9174. 2016.
|
|
22
|
Othman N, In LLA, Harikrishna JA and
Hasima N: Bcl-xL Silencing induces alterations in hsa-miR-608
expression and subsequent cell death in A549 and SKLU1 human lung
adenocarcinoma cells. PLoS One. 10:e817352013. View Article : Google Scholar
|
|
23
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatic resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
|
|
25
|
Reynisdóttir I, Polyak K, Iavarone A and
Massagué J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce
cell cycle arrest in response to TGF-beta. Genes Dev. 9:1831–1845.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Calin GA, Liu CG, Sevignani C, Ferracin M,
Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ciafrè SA, Galardi S, Mangiola A, Ferracin
M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wozniak MB, Scelo G, Muller DC, Mukeria A,
Zaridze D and Brennan P: Circulating microRNAs as non-invasive
biomarkers for early detection of non-small-cell lung cancer. PLoS
One. 10:e01250262015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nadal E, Truini A, Nakata A, Lin J, Reddy
RM, Chang AC, Ramnath N, Gotoh N, Beer DG and Chen G: A novel serum
4-microRNA signature for lung cancer detection. Sci Rep.
5:124642015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai
Y, Xiao L, Huang S, Chen L, Guo Z, et al: MicroRNA-486 as a
biomarker for early diagnosis and recurrence of non-small cell lung
cancer. PLoS One. 10:e01342202015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bianchi F: Lung cancer early detection:
The role of circulating microRNAs. EBioMedicine. 2:1278–1279. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su Y, Fang H and Jiang F: Integrating DNA
methylation and microRNA biomarkers in sputum for lung cancer
detection. Clin Epigenetics. 8:1092016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu C, Zheng Y, Lian D, Ye S, Yang J and
Zeng Z: Analysis of microRNA expression profile identifies novel
biomarkers for non-small cell lung cancer. Tumori. 101:104–110.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wei J, Liu LK, Gao W, Zhu C-J, Liu Y-Q,
Cheng T and Shu YQ: Reduction of plasma microRNA-21 is associated
with chemotherapeutic response in patients with non-small cell lung
cancer. Chin J Cancer Res. 23:123–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Enfield KS, Stewart GL, Pikor LA, Alvarez
CE, Lam S, Lam WL and Chari R: MicroRNA gene dosage alterations and
drug response in lung cancer. J Biomed Biotechnol. 2011:4746322011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Saito M, Shiraishi K, Matsumoto K,
Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H,
Watanabe S, Tsuta K, et al: A three-microRNA signature predicts
responses to platinum-based doublet chemotherapy in patients with
lung adenocarcinoma. Clin Cancer Res. 20:4784–4793. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pedroza-Torres A, Fernández-Retana J,
Peralta-Zaragoza O, Jacobo-Herrera N, Cantú de Leon D, Cerna-Cortés
JF, Lopez-Camarillo C and Pérez-Plasencia C: A microRNA expression
signature for clinical response in locally advanced cervical
cancer. Gynecol Oncol. 142:557–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zheng J, Deng J, Xiao M, Yang L, Zhang L,
You Y, Hu M, Li N, Wu H, Li W, et al: A sequence polymorphism in
miR-608 predicts recurrence after radiotherapy for nasopharyngeal
carcinoma. Cancer Res. 73:5151–5162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin M, Gu J, Eng C, Ellis LM, Hildebrandt
MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, et al: Genetic
polymorphisms in microRNA-related genes as predictors of clinical
outcomes in colorectal adenocarcinoma patients. Clin Cancer Res.
18:3982–3991. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ying HQ, Peng HX, He BS, Pan YQ, Wang F,
Sun HL, Liu X, Chen J, Lin K and Wang SK: MiR-608, pre-miR-124-1
and pre-miR26a-1 polymorphisms modify susceptibility and
recurrence-free survival in surgically resected CRC individuals.
Oncotarget. 7:75865–75873. 2016.PubMed/NCBI
|
|
42
|
Ryan BM, McClary AC, Valeri N, Robinson D,
Paone A, Bowman ED, Robles AI, Croce C and Harris CC: rs4919510 in
hsa-mir-608 is associated with outcome but not risk of colorectal
cancer. PLoS One. 7:e363062012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang AJ, Yu KD, Li J, Fan L and Shao ZM:
Polymorphism rs4919510:C>G in mature sequence of human
microRNA-608 contributes to the risk of HER2-positive breast cancer
but not other subtypes. PLoS One. 7:e352522012. View Article : Google Scholar :
|
|
44
|
Hashemi M, Bizhani F, Danesh Hiva D,
Narouie B, Sotoudeh M, Radfar MH, Ramezani MH, Bahari G, Taheri M
and Ghavami S: MiR-608 rs4919510 C>G polymorphism increased the
risk of bladder cancer in an Iranian population. AIMS Genet.
3:212–218. 2016. View Article : Google Scholar
|
|
45
|
Hashemi M, Sanaei S, Rezaei M, Bahari G,
Hashemi SM, Mashhadi MA, Taheri M and Ghavami S: miR-608 rs4919510
C>G polymorphism decreased the risk of breast cancer in an
Iranian subpopulation. Exp Oncol. 38:57–59. 2016.PubMed/NCBI
|
|
45
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Martelli AM, Tabellini G, Bressanin D,
Ognibene A, Goto K, Cocco L and Evangelisti C: The emerging
multiple roles of nuclear Akt. Biochim Biophys Acta.
1823:2168–2178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray
MR, Snow BE, Ayala R, Danino M, Karlan BY and Slamon DJ:
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation
of beta1 integrins, increased invasion, and metastasis of human
breast and ovarian cancer cells. Cancer Res. 63:196–206.
2003.PubMed/NCBI
|
|
48
|
Santi SA and Lee H: Ablation of Akt2
induces autophagy through cell cycle arrest, the downregulation of
p70S6K, and the deregulation of mitochondria in MDA-MB-231 cells.
PLoS One. 6:e146142011. View Article : Google Scholar
|
|
49
|
Altomare DA, Tanno S, De Rienzo A,
Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP and Testa JR:
Frequent activation of AKT2 kinase in human pancreatic carcinomas.
J Cell Biochem. 87:470–476. 2002. View Article : Google Scholar
|
|
50
|
Xu X, Sakon M, Nagano H, Hiraoka N,
Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, et
al: Akt2 expression correlates with prognosis of human
hepatocellular carcinoma. Oncol Rep. 11:25–32. 2004.
|
|
51
|
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X,
Jiang C, Coppola D, Nicosia SV and Cheng JQ: Frequent activation of
AKT2 and induction of apoptosis by inhibition of
phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Oncogene. 19:2324–2330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cheng JQ, Godwin AK, Bellacosa A, Taguchi
T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: AKT2, a
putative oncogene encoding a member of a subfamily of
protein-serine/threonine kinases, is amplified in human ovarian
carcinomas. Proc Natl Acad Sci USA. 89:9267–9271. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ringel MD, Hayre N, Saito J, Saunier B,
Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD and Saji M:
Overexpression and overactivation of Akt in thyroid carcinoma.
Cancer Res. 61:6105–6111. 2001.PubMed/NCBI
|
|
54
|
Cui Y, Wang Q, Wang J, Dong Y, Luo C, Hu G
and Lu Y: Knockdown of AKT2 expression by RNA interference inhibits
proliferation, enhances apoptosis, and increases chemosensitivity
to the anticancer drug VM-26 in U87 glioma cells. Brain Res.
1469:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mure H, Matsuzaki K, Kitazato KT,
Mizobuchi Y, Kuwayama K, Kageji T and Nagahiro S: Akt2 and Akt3
play a pivotal role in malignant gliomas. Neuro Oncol. 12:221–232.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee MW, Kim DS, Lee JH, Lee BS, Lee SH,
Jung HL, Sung KW, Kim HT, Yoo KH and Koo HH: Roles of AKT1 and AKT2
in non-small cell lung cancer cell survival, growth, and migration.
Cancer Sci. 102:1822–1828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Balsara BR, Pei J, Mitsuuchi Y, Page R,
Klein-Szanto A, Wang H, Unger M and Testa JR: Frequent activation
of AKT in non-small cell lung carcinomas and preneoplastic
bronchial lesions. Carcinogenesis. 25:2053–2059. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Attoub S, Arafat K, Hammadi NK, Mester J
and Gaben AM: Akt2 knock-down reveals its contribution to human
lung cancer cell proliferation, growth, motility, invasion and
endothelial cell tube formation. Sci Rep. 5:127592015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Qiao J, Lee S, Paul P, Qiao L, Taylor CJ,
Schlegel C, Colon NC and Chung DH: Akt2 regulates metastatic
potential in neuroblastoma. PLoS One. 8:e563822013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liang Z, Wang X, Xu X, Xie B, Ji A, Meng
S, Li S, Zhu Y, Wu J, Hu Z, et al: MicroRNA-608 inhibits
proliferation of bladder cancer via AKT/FOXO3a signaling pathway.
Mol Cancer. 16:962017. View Article : Google Scholar : PubMed/NCBI
|
